Viyash Q2 FY27 slides: revenue up 16%, margin expansion continues
Viyash Scientific Limited reported its Q2 FY27 financials on November 13, 2026, highlighting continued growth and strategic progress. Revenue from operations increased 16.2% year-over-year to ₹9,879 million, while profit after tax rose 16.1% to ₹847 million. EBITDA before ESOP costs grew 10.3% to ₹2,077 million, yet the EBITDA margin contracted 110 basis points to 21.0%.
Dr. Hari Babu Bodepudi, Managing Director and Group CEO, noted the company's momentum as an integrated platform across animal and human health. The first half of FY27 showed even stronger performance, with revenues growing 17.8% to ₹19,343 million and EBITDA expanding 29.9% to ₹4,124 million. Profit after tax surged 49.4% to ₹1,639 million, with adjusted profit after tax reaching ₹2,040 million.
The company achieved deleveraging, with net debt to EBITDA falling to 0.0x in Q2 FY27. Sales increased consistently from ₹7,292 million in Q1 FY25 to ₹9,879 million in Q2 FY27. Gross margin improved to 53.7% in Q2 FY27, though slightly below the prior quarter's 55.5%. Revenue grew in forms of formulations, APIs, and strategic investments, including the BioForLife acquisition in Italy and new oncology capabilities at a Jeedimetla R&D facility.
Additionally, the company is building companion animal manufacturing capacity in Ambernath and expanding API manufacturing at Viyash-IV in Nalgonda.
Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
